Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners

被引:2
|
作者
Yiallouridou, Christina [1 ]
Acton, Jennifer H. [1 ]
Banerjee, Sanjiv [2 ]
Waterman, Heather [3 ]
Wood, Ashley [1 ]
机构
[1] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, Wales
[2] Cardiff & Vale Univ Hlth Board, Ophthalmol, Cardiff, Wales
[3] Cardiff Univ, Healthcare Sci, Cardiff, Wales
来源
BMJ OPEN | 2023年 / 13卷 / 08期
关键词
QUALITATIVE RESEARCH; PAIN MANAGEMENT; OPHTHALMOLOGY; NEEDLE SIZE; RANIBIZUMAB; EXPERIENCES; ANXIETY; ANESTHESIA; FEAR;
D O I
10.1136/bmjopen-2022-069625
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesOcular pain is a commonly reported finding in the intravitreal injection procedure, but post-injection experiences and patient adherence to treatment remain underexplored. We therefore aimed to identify key variations in the intravitreal injection procedure that may influence pain, and to gain insights into the post-injection experience and treatment adherence from the perspective of patients and practitioners. DesignQualitative semistructured interview study using reflexive thematic analysis of transcripts. SettingHospital Eye Clinic in Wales, UK. Interviews were conducted between May and September 2019. ParticipantsPurposive sample of patients aged & GE;50 years with neovascular age-related macular degeneration and no other retinal pathology who had received at least six intravitreal injections, and practitioners including ophthalmologists, registered nurses and optometrists who performed intravitreal injections at the research site. ResultsData saturation was reached with 21 interviews: 14 patients and 7 practitioners. Three main themes were identified from the analysis: fear of losing eyesight and treatment anxiety influence patient adherence to treatment, variability in pain experience during treatment, and post-injection experience and impact on patient recovery. To reassure patients feeling apprehensive about the injections, practitioners promoted safety and trust, and used techniques to manage anxiety. Key variations that may influence pain identified were application of antiseptic or anaesthetic, injecting methods and communication. During injection, patients reported a dull-aching and sharp pain, contrary to practitioners' perspective of feeling a 'pressure'. Patients described prolonged soreness and irritation of up to 36 hours post-injection affecting their sleep and recovery. ConclusionEstablishing rapport supported patients to recognise the necessity of ongoing treatment to prevent sight loss; however, inadequate pain management led to undesirable outcomes. Practitioners should use pain assessment tools during and immediately after injection and provide ongoing consistent information to help patients manage pain at home.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Bimonthly injections of ranibizumab for age-related macular degeneration
    Sawada, Tomoko
    Wang, Xiying
    Sawada, Osamu
    Saishin, Yoshitsugu
    Ohji, Masahito
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [22] Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study
    Smit, Cornelis
    Wiertz-Arts, Karin
    van de Garde, Ewoudt M. W.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (06) : 561 - 567
  • [23] Quality of life survey of 3,738 patients treated with intravitreal injections for age-related macular degeneration
    Uzzan, J.
    Haddad, M.
    Salame, N.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2024, 47 (03):
  • [24] Dry Eye and Meibomian Gland Dysfunction in Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Injections
    Kiyat, Pelin
    Palamar, Melis
    Nalcaci, Serhad
    Akkin, Cezmi
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2022, 52 (03): : 157 - 161
  • [25] Ultrasonographic findings in vitreous of age-related macular degeneration patients treated with intravitreal anti-vegf injections
    Mato Gondelle, Tamara
    Bande, Manuel F.
    Paniagua, Laura
    Rodriguez Cid, Maria Jose
    Abraldes Lopez-Veiga, Maximino
    Fernandez Rodriguez, Maribel
    Jose Blanco, Maria
    Pineiro, Antonio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [26] A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration
    Dae Hyun Park
    Hae Jung Sun
    Sung Jin Lee
    International Ophthalmology, 2017, 37 : 1205 - 1214
  • [27] Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration
    Jost B. Jonas
    Ingrid Kreissig
    Robert Degenring
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2002, 240 : 872 - 873
  • [28] Multiple retinal vein thromboses after intravitreal aflibercept injections for age-related macular degeneration
    Haruta, Masatoshi
    Ishibashi, Koki
    Ishibashi, Yumi
    Dake, Shotaro
    Sasaki, Kensuke
    Noda, Rie
    Yoshida, Yumiko
    Yoshida, Shigeo
    ACTA OPHTHALMOLOGICA, 2020, 98 (04) : E527 - E528
  • [29] Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration
    Nishimura, Tomoharu
    Machida, Shigeki
    Harada, Tomomi
    Kurosaka, Daijiro
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 1073 - 1082
  • [30] Angiographic Regression Patterns After Intravitreal Ranibizumab Injections for Neovascular Age-Related Macular Degeneration
    Thi Ha Chau Tran
    Querques, Giuseppe
    Forzy, Gerard
    Souied, Eric H.
    OPHTHALMIC SURGERY LASERS & IMAGING, 2011, 42 (06) : 498 - 508